Improvement of potential therapeutic value of tumor necrosis-α (TNF-α) by charge modulation in the tip region

European Cytokine Network

Volumn 16, Issue 1, 2005, Pages 17-26

  Fonda, Irena ^a   Pernuš, Mojca ^b   Gaberc Porekar, Vladka ^a   Kenig, Maja ^b   Štalc, Anton ^b   Meager, Anthony ^c   Menart, Viktor ^a,b  

^a NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^b Lek dd   (Slovenia)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Basic analogues; Heparan sulphate; Isoelectric point; KYM 1D4; L929; TNF

Indexed keywords

HEPARAN SULFATE; HEPARIN LYASE; LK 801; LK 803; LK 804; LK 805; LK 820; LK 822; LK 823; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR DERIVATIVE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CELL LINE; CELL STRAIN EAHY926; CELL STRAIN HEPA 1-6; CELL STRAIN KYM 1D4; CELL STRAIN L 929; CELL STRAIN WEHI 164; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG PURIFICATION; DRUG STORAGE; HELA CELL; HUMAN; HUMAN CELL; ISOELECTRIC FOCUSING; ISOELECTRIC POINT; MOLECULAR CLONING; MOUSE; NONHUMAN;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; HEPARIN LYASE; HEPARITIN SULFATE; HUMANS; ISOELECTRIC POINT; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 16444381697     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991; 285: 199.
2. Aggarwal BB. Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-kappa B. Ann Rheum Dis 2000; 59(Suppl 1): i6.
3. Spriggs DR, Sherman ML, Frei E, Kufe DW. Clinical studies with tumour necrosis factor. Ciba Found Symp 1987; 131: 206.
4. Taguchi T, Sohmura Y. Clinical studies with TNF. Biotherapy 1991; 3: 177.
5. Barbara JA, Van Ostade X, Lopez A. Tumour necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective. Immunol Cell Biol 1996; 74: 434.
6. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52.
7. Lodato RF, Feig B, Akimaru K, Soma G, Klostergaard J. Hemodynamic evaluation of recombinant human tumor necrosis factor (TNF)-alpha, TNF-SAM2 and liposomal TNF-SAM2 in an anesthetized dog model. J Immunother Emphasis Tumor Immunol 1995; 17: 19.
8. Corti A, Marcucci F. Tumour necrosis factor: strategies for improving the therapeutic index. J Drug Target 1998; 5: 403.
9. Tsutsumi Y, Kihira T, Tsunoda S, Kanamori T, Nakagawa S, Mayumi T. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. Br J Cancer 1995; 71: 963.
10. Gautam SC, Xu YX, Pindolia KR, Yegappan R, Janakiraman N, Chapman RA. TNF-alpha gene therapy with myeloid progenitor cells lacks the toxicities of systemic TNF-alpha therapy. J Hematother 1999; 8: 237.
11. Yasui K, Nakamura Y. Positively charged liposomes containing tumor necrosis factor in solid tumors. Biol Pharm Bull 2000; 23: 318.
12. Lejeune FJ, Lienard D, Eggermont A, et al. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J Cell Biochem 1994; 56: 52.
13. Lejeune FJ, Kroon BB, Di F, et al. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am 2001; 10: 821; ix.
14. Nakamoto T, Inagawa H, Takagi K, Soma G. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Anticancer Res 2000; 20: 4087.
15. Van Ostade X, Vandenabeele P, Everaerdt B, et al. Human TNF mutants with selective activity on the p55 receptor. Nature 1993; 361: 266.
16. Masegi T, Nakamura S, Fukuoka M, et al. Hyperactive TNF-alpha derivatives with combinational mutations in the amino and carboxyl-terminal regions. Biotechnol Lett 1993; 15: 1107.
17. Masegi T, Kato A, Kitai K, et al. Characterization of a novel human tumor necrosis factor-alpha mutant with increased cytotoxic activity. Jpn J Cancer Res 1995; 86: 72.
18. Novaković S, Menart V, Gaberc-Porekar V, et al. New TNF-alpha analogues: a powerful but less toxic biological tool against tumours. Cytokine 1997; 9: 597.
19. Creasey AA, Doyle LV, Reynolds MT, Jung T, Lin LS, Vitt CR. Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res 1987; 47: 145.
20. Nakamura S, Kato A, Masegi T, et al. A novel recombinant tumor necrosis factor-alpha mutant with increased anti-tumor activity and lower toxicity. Int J Cancer 1991; 48: 744.
21. Miyata K, Kato M, Shikama H, et al. A YIGSR-containing novel mutein without the detrimental effect of human TNF-alpha of enhancing experimental pulmonary metastasis. Clin Exp Metastasis 1992; 10: 267.
22. Shikama H, Miyata K, Sakae N, et al. A novel mutein of TNF-alpha containing the arg-gly-asp sequence shows reduced toxicity in intestine. Mediat Inflam 1994; 3: 111.
23. Terlikowski SJ. Local immunotherapy with rhTNF-alpha mutein induces strong antitumor activity without overt toxicity-a review. Toxicology 2002; 174: 143.
24. Soma G, Kitahara N, Tsuji Y, et al. Improvement of cytotoxicity of tumor necrosis factor (TNF) by increase in basicity of its N-terminal region. Biochem Biophys Res Commun 1987; 148: 629.
25. Sato T, Yamauchi N, Sasaki H, et al. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration. Cancer Res 1998; 58: 1677.
26. Meager A, Leung H, Woolley J. Assays for tumour necrosis factor and related cytokines. J Immunol Methods 1989; 116: 1.
27. Soma G, Tsuji Y, Tanabe Y, et al. Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors produced by THP-1 cells. J Biol Response Mod 1988; 7: 587.
28. Eck MJ, Sprang SR. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem 1989; 264: 17595.
29. Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993; 73: 431.
30. Meager A. A cytotoxicity assay for tumour necrosis factor using a human rhabdomyosarcoma cell line. J Immun Methods 1991; 144: 141.
31. Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc N Acad Sciences USA 1983; 80: 3734.
32. Kunkel TA, Roberts JD, Zakour RA. Rapid and Efficient Site-specific Mutagenesis without Phenotypic Selection. Methods Enzymol 1987; 154: 367.
33. Menart V, Jevsevar S, Vilar M, Trobis A, Pavko A. Constitutive versus thermoinducible expression of heterologous proteins in Escherichia coli based on strong PR,PL promoters from phage lambda. Biotechnol Bioeng 2003; 83: 181.
34. Davis JM, Narachi MA, Alton NK, Arakawa T. Structure of human tumor necrosis factor alpha derived from recombinant DNA. Biochemistry 1987; 26: 1322.
35. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55.
36. Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods 1984; 68: 167.
37. Gatanaga T, Noguchi K, Tanabe Y, Inagawa H, Soma G, Mizuno D. Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-alpha in vivo. J Biol Response Mod 1989; 8: 278.
38. Ito R, Matsumoto H, Uchida K, et al. Novel muteins of human tumor necrosis factor alpha. Biochim Biophys Acta 1991; 1096: 245.
39. Shikama H, Miyata K, Sakae N, et al. Novel mutein of tumor necrosis factor alpha (F4614) with reduced hypotensive effect. J Interferon Cytokine Res 1995; 15: 677.
40. Guo D, Shen B, Dong X, Qiu Q, Xu X. Creation of a high cytotoxic active human tumor necrosis factor having the truncated and more basic amino terminus. Biochem Biophys Res Commun 1995; 207: 927.
41. Fonda I, Kenig M, Gaberc-Porekar V, Pristovsek P, Menart V. Attachment of histidine tags to recombinant tumor necrosis factor-alpha drastically changes its properties. Scient World J 2002; 2: 1312.
42. Lucas R, Magez S, Deleys R, et al. Mapping the Lectin-Like Activity of Tumor Necrosis Factor. Science 1994; 263: 814.
43. Lucas R, Echtenacher B, Sablon E, et al. Generation of a mouse tumor necrosis factor mutant with antiperitonitis and desensitization activities comparable to those of the wild type but with reduced systemic toxicity. Infect Immun 1997; 65: 2006.
44. Lucas R, Montesano R, Pepper MS, et al. Lectin-deficient TNF mutants display comparable anti-tumour but reduced prometastatic potential as compared to the wild-type molecule. Int J Cancer 2001; 91: 543.
45. de Wilt JHW, tenHagen TLM, DeBoeck G, VanTiel ST, deBruijn EA, Eggermont AMM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 1000.
46. Menart V, Fonda I, Kenig M, Gaberc-Porekar V. Increased in vitro cytotoxicity of TNF-alpha analog LK-805 is based on the interaction with cell surface heparan sulfate proteoglycan. Ann N Y Acad Sci 2002; 973: 194.
47. Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991; 252: 1705.
48. Sekiguchi M, Shiroko Y, Suzuki T, Imada M, Miyahara M, Fujii G. Characterization of a human rhabdomyosarcoma cell strain in tissue culture. Biomed Pharmacother 1985; 39: 372.
49. Lever R, Page C. Glycosaminoglycans, airways inflammation and bronchial hyperresponsiveness. Pulm Pharmacol Ther 2001; 14: 249.
50. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA, Goeddel DV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 1991; 88: 9292.
51. Kramer SM, Aggarwal BB, Eessalu TE, et al. Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. Cancer Res 1988; 48: 920.
52. Lewis M, Tartaglia LA, Lee A, et al. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 1991; 88: 2830.
53. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992; 13: 151.
54. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signalling by the 55-kDa TNF receptor. J Biol Chem 1993; 268: 18542.